B
ORKA

Braidwell’s Oruka Therapeutics ORKA Stock Holding History

Braidwell’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-84,795
Closed -$2.57M – 101
2025
Q4 		$2.57M Sell
84,795
-1,297,555
-94% -$36.2M 0.08% 71
2025
Q3 		$26.6M Sell
1,382,350
-142,492
-9% -$2.11M 0.79% 37
2025
Q2 		$17.1M Sell
1,524,842
-47,584
-3% -$496K 0.58% 43
2025
Q1 		$16.1M Buy
1,572,426
+424,750
+37% +$5.3M 0.57% 46
2024
Q4 		$27.1M Buy
1,147,676
+631,950
+123% +$15.4M 0.8% 43
2024
Q3 		$12.6M Buy
+515,726
New +$17.9M 0.36% 60

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Braidwell's ORKA Position: Q1 2026 in Review

Braidwell sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 84,795 shares — an estimated $2.57M sold.

Braidwell first reported a position in ORKA in Q3 2024 and held it in 6 quarters. The position peaked at $27.1M in Q4 2024. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Braidwell reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Braidwell sold 84,795 Oruka Therapeutics shares in Q1 2026, an estimated $2.57M.
  • Braidwell first reported a position in Oruka Therapeutics in Q3 2024 and held it in 6 quarters.
  • Braidwell's Oruka Therapeutics position peaked at $27.1M in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.